HER-2 expression in canine morphologically normal, hyperplastic and neoplastic mammary tissues and its correlation with the clinical outcome

Research in Veterinary Science

Volumn 94, Issue 2, 2013, Pages 299-305

  Ressel, Lorenzo ^a,c   Puleio, Roberto ^b   Loria, Guido Ruggero ^b   Vannozzi, Iacopo ^a   Millanta, Francesca ^a   Caracappa, Santo ^b   Poli, Alessandro ^a  

^a UNIVERSITY OF PISA   (Italy)

^b ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA SICILIA A MIRRI   (Italy)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Dog; HER 2; Immunohistochemistry; Mammary tumours; Overall survival; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANIMAL TISSUE; ARTICLE; BREAST ADENOMA; BREAST CARCINOMA; BREAST DYSPLASIA; BREAST HYPERPLASIA; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MITOSIS INDEX; NONHUMAN; ONCOGENE NEU; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOMA; ANIMALS; CARCINOMA; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; RECEPTOR, ERBB-2; SURVIVAL RATE;

CANIS FAMILIARIS;

EID: 84873745200     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2012.09.016     Document Type: Article

References (32)

1. Ahern T.E., Bird R.C., Bird A.E., Wolfe L.G. Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. American Journal of Veterinary Research 1996, 57:693-696.
2. Almasri N.M., Al Hamad.M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Research 2005, 7:R598-R604.
3. Chang S.-C., Chang C.-C., Chang T.-J., Wong M.-L. Prognostic factors associated with survival 2years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002). Journal of the American Veterinary Medical Association 2005, 227:1625-1629.
4. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Simon D.J. Multinational study of the efficacy and safety of humanized anti HER-2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology 1999, 17:2639-2648.
5. De Maria R., Olivero M., Iussich S., Nakaichi M., Murata T., Biolatti B., Di Renzo M.F. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Research 2005, 65:907-912.
6. Dutra A.P., Granja N.V., Schmitt F.C., Cassali G.D. C-erbB-2 expression and nuclear pleomorphism in canine mammary tumors. Brazilian Journal of Medical and Biological Research 2004, 37:1673-1681.
7. Eccles S.A. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. Journal of Mammary Gland Biology and Neoplasia 2001, 6:393-406.
8. Elston C.W., Ellis I.O. Pathological prognostica factors in breast cancer. I. Value of histological grade breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
9. Gramlich T.L., Cohen C., Fritsch C., DeRose P.B., Gansler T. Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction. Anatomic Pathology 1994, 101:493-499.
10. Gutierrez C., Schiff R. HER2: biology, detection, and clinical implications. Archives of Pathology & Laboratory Medicine 2011, 135:55-62.
11. Hanna W., Kahn H.J., Trudeau M. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Modern Pathology 1999, 12:827-834.
12. Hortobagyi G.N. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Seminars in Oncology 2001, 28(Suppl. 18):43-47.
13. Hsu W.-L., Huang H.-M., Liao J.-W., Wong M.-L., Chang S.-C. Increased survival in dogs with malignant mammary tumours overexpressing HER-protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. The Veterinary Journal 2009, 180:116-123.
14. Jacobs T.W., Gown A.M., Yazjii H., Barnes M.J., Schnitt S.J. Comparison of fluorescence in situ hybridisation and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. Journal of Clinical Oncology 1999, 17:1974-1982.
15. Kaya H., Ragazzini T., Aribal E., Güney I., Kotilo L.E. Her-2/neu Gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma. Pathology and Oncology Research 2001, 7:279-283.
16. Lana S.E., Rutteman G.R., Withrow S.J. Tumours of the mammary gland. Small Animal Clinical Oncology 2007, 619-936. Saunders, Elsevier, St. Louis, MI, USA. fourth ed. S.J. Withrow, D.M. Vail (Eds.).
17. Leal C.B., Schimtt F.C., Bento M.J., Maia N.C., Lopes C. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 1995, 75:2123-2131.
18. Leal C.B., Henrique R., Monteiro P., Lopes C., Bento M.J., De Suosa C.P., Lopes P., Olson S., Silva M.A., Page D.L. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Human Pathology 2001, 32:487-493.
19. Lian S.C., Tan P.H. CerbB2 status in breast cancer: pathologic issues. Annals Academy Science of Singapore 2002, 31:793-798.
20. Martin de las Mulas J., Ordá S., Millán Y., Fernández-Soria V., Ramón y Cajal S. Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study. Breast Cancer Research and Treatment 2003, 80:363-367.
21. Millanta F., Calandrella M., Citi S., Della Santa D., Poli A. Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Veterinary Pathology 2005, 42:30-34.
22. Misdorp, W., Else, R.W., Hellmén, E., Lipscomb, T.P., 1999. Histological Classification of Mammary Tumors of the Dog and the Cat, second series, vol. VII, Armed Forces Institute of Pathology, American Registry of Pathology, Washington, DC and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, pp. 1-59.
23. Ordás J., Millán Y., Dios R., Reymundo C., de Las Mulas J.M. Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 2007, 7:179.
24. Rasotto R., Caliari D., Castagnaro M., Zanetti R., Zappulli V. An immunohistochemical study of HER-2 expression in feline mammary tumours. Journal of Comparative Pathology 2011, 144:170-179.
25. Révillion F., Bonneterre J., Peyrat J.P. ERBB2 oncogene in human breast cancer and its clinical significance. European Journal of Cancer 1998, 34:791-808.
26. Rungsipipat A., Tateyama S., Yamaguchi R., Uchida K., Miyoshi N., Hayashi T. Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. Journal of Veterinary Medical Science 1999, 61:27-32.
27. Selvarajan S., Bay B.H., Chng M.J., Tan P.H. The HercepTest and routine C-erbB-2 immunohistochemistry in breast cancer: any difference?. Annals Academy Science of Singapore 2004, 33:473-476.
28. Thomson T.A., Hayes M.M., Spinelli J.J., Hilland E., Sawrenko C., Phillips D., Dupuis B., Parker R.L. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Modern Pathology 2001, 14:1079-1086.
29. Tsuda H., Hirohashi S., Shimosata Y., Hirota T., Tsugane S., Watanabe S., Tereda M., Yamamoto H. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer 1990, 65:1794-1800.
30. Tsuda H., Tsugane S., Fukotomi T., Nanasawa T., Yamamoto H., Hirohashi S. Prognostic factors for recurrent breast cancer: univariate and multivariate analysis including histologic grade and amplification of the c-erbB-2 proto-oncogene. Japanese Journal of Clinical Oncology 1992, 22:244-249.
31. Van de Vijver M.J. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). European Journal of Cancer 2001, 37:S11-S17.
32. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer. Journal of Clinical Oncology 2002, 20:719-726.